Compelling AI-generated images start with well-crafted prompts. In this follow-up to our Amazon Nova Canvas Prompt Engineering Guide, we showcase a curated gallery of visuals generated by Nova Canvas—categorized by real-world use cases—from marketing and product visualization to concept art and design exploration. Each image is paired with the promptContinue Reading
Amazon Rekognition people pathing is a machine learning (ML)–based capability of Amazon Rekognition Video that users can use to understand where, when, and how each person is moving in a video. This capability can be used for multiple use cases, such as for understanding: Retail analytics – Customer flow inContinue Reading
Amazon Lookout for Vision, the AWS service designed to create customized artificial intelligence and machine learning (AI/ML) computer vision models for automated quality inspection, will be discontinuing on October 31, 2025. New customers will not be able to access the service effective October 10, 2024, but existing customers will beContinue Reading
This post is co-written with Joe Clark from Domo. Data insights are crucial for businesses to enable data-driven decisions, identify trends, and optimize operations. Traditionally, gaining these insights required skilled analysts using specialized tools, which can make the process slow and less accessible. Generative artificial intelligence (AI) has revolutionized thisContinue Reading
Maksim Labkouski/iStock via Getty Images NCR Voyix (NYSE:VYX) edged higher by 2% amid a report that it’s evaluating the sale of its digital banking business. NCR Voyix (VYX) is trying to get as much as $3 billion for the unit and has hired Goldman Sachs to solicit interest from possibleContinue Reading
Alexander Farnsworth Walmart (NYSE:WMT) has reportedly held talks with parties such as Humana (HUM) over a possible sale of its financially troubled healthcare centers business. According to Fortune, Walmart has been in discussions with several parties, including health insurance companies. Fortune cited Humana as one of the parties that hasContinue Reading
Zhanna Hapanovich TRACON Pharmaceuticals (OTC:TCON) said it is discontinuing development of its oncology drug candidate envafolimab after a key clinical trial failed to meet its primary endpoint and will concentrate instead on exploring strategic alternatives for the company. TRACON said that the study, ENVASARC, failed to meet its primary endpointContinue Reading
